DeuterOncology

Liège ·KBO/BCE: BE 0754.971.388

Loading dossier…

Year closed	Due by	Filed	Variance	Reference
31-12-2025	31-07-2026	nothing on record	not filed	-
31-12-2024	31-07-2025	27-06-2025	34 d early	2025-00210166
31-12-2023	31-07-2024	20-06-2024	41 d early	2024-00171012
31-12-2022	31-07-2023	07-07-2023	24 d early	2023-00214976
31-12-2021	31-07-2022	15-09-2022	46 d late	2022-20429634

Metric	This company	Sector median	Position in the sector
Solvency	76.0%	46.9%	better than 75% of 46 sector peers
Net result	€-2.11M	€-1k	better than 7% of 46 sector peers
Equity	€966k	€108k	better than 75% of 46 sector peers
Gross operating margin	€-1.99M	€28k	better than 5% of 42 sector peers
Total assets	€1.27M	€284k	better than 68% of 46 sector peers

Line item	Code	2024
Balance sheet, Assets
TOTAL ASSETS	20/58	€1.27M
Fixed assets	21/28	€232k
Intangible fixed assets	21	€2k
Financial fixed assets	28	€230k
Current assets	29/58	€1.04M
Amounts receivable within one year	40/41	€172k
Cash & bank	54/58	€829k
Balance sheet, Equity & liabilities
TOTAL EQUITY & LIABILITIES	10/49	€1.27M
Equity	10/15	€966k
Contributions / capital	10/11	€8.60M
Accumulated profits (losses)	14	€-7.63M
Amounts payable	17/49	€306k
Amounts payable within one year	42/48	€304k
Trade debts payable within one year	44	€304k
Income statement
Gross operating margin	9900	€-1.99M
Operating result	9901	€-2.29M
Financial income	75	€165k
Financial charges	65	€3k
Result before taxes	9903	€-2.13M
Income taxes	67/77	€-12k
Net result for the period	9904	€-2.11M
Result to be appropriated	9905	€-2.11M

Summary

NACE primary	Vervaardiging van farmaceutische grondstoffen(21100)
Legal form	Public limited company(014)
Incorporation	28-09-2020
Status	Active
Postal code	4000